Navigation Links
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline: March 7, 2017
Date:1/9/2017

NEW YORK, Jan. 9, 2017 /PRNewswire/ -- Attorney Advertising -- NEW YORK Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Agile Therapeutics, Inc. ("Agile" or the "Company") (NASDAQ: AGRX) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased General Cable securities between March 9, 2016 and January 3, 2017, both dates inclusive (the "Class Period"). Such investors are advised to join this case by visiting the firm's site: http://www.bgandg.com/agrx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

The complaint filed in this lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (2) that over half of patients in its "Secure" Phase 3 Study dropped out of the study early; (3) that the Twirla patch therefore allegedly had a slim chance for FDA approval; and (4) that, consequently, Defendants' statements about Agile's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On January 3, 2017, after market hours, Agile revealed data from its Phase 3 SECURE study evaluating Twirla, its combined hormonal contraceptive patch, following the U.S. Food and Drug Administration request, following its rejection of Agile's 2013 initial marketing application. During a press release, Agile indicated "positive top-line results" in the study, but related that 1.7% of subjects suffered "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." Additionally, 51.4% of subjects withdrew the study. Following this news, Agile stock has dropped as much as $3.18 per share, or 63.6%, to $1.82 during intraday trading on January 4, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: http://www.bgandg.com/agrx  or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Agile you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-agile-therapeutics-inc-agrx-and-lead-plaintiff-deadline-march-7-2017-300387585.html


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Medifirst Solutions, Inc. Announces Further Update To Shareholders
2. Hadasit Bio-Holdings CEO Letter to Shareholders
3. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
4. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
5. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
6. Adamis Pharmaceuticals CEO Provides Update for Shareholders
7. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
8. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
9. BioRestorative Therapies Provides Company Updates with Shareholder Letter
10. Strategic Initiatives, Executive Transitions, and Strengthened Portfolios to Increase Shareholder Value - Research Report on Trius, HCA, Alere, UHS, and Bio-Reference
11. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
(Date:10/4/2017)... Oct. 4, 2017  GCE Solutions, a global clinical research organization ... document anonymization solution on October 4, 2017. Shadow is designed to ... comply with policy 0070 of the European Medicines Agency (EMA) in ... ... ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
Breaking Biology News(10 mins):